X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs VENUS REMEDIES - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA VENUS REMEDIES AUROBINDO PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 14.5 -1.0 - View Chart
P/BV x 2.9 0.1 3,953.4% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 AUROBINDO PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
VENUS REMEDIES
Mar-18
AUROBINDO PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs809126 642.6%   
Low Rs50461 824.9%   
Sales per share (Unadj.) Rs281.1301.8 93.1%  
Earnings per share (Unadj.) Rs41.4-24.9 -166.3%  
Cash flow per share (Unadj.) Rs50.92.5 1,999.5%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.4293.3 68.0%  
Shares outstanding (eoy) m585.8812.34 4,747.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.30.3 753.9%   
Avg P/E ratio x15.9-3.8 -422.3%  
P/CF ratio (eoy) x12.936.7 35.1%  
Price / Book Value ratio x3.30.3 1,032.9%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,6301,154 33,336.2%   
No. of employees `00017.30.9 1,873.7%   
Total wages/salary Rs m21,308393 5,420.6%   
Avg. sales/employee Rs Th9,500.74,026.1 236.0%   
Avg. wages/employee Rs Th1,229.4425.0 289.3%   
Avg. net profit/employee Rs Th1,397.9-331.8 -421.3%   
INCOME DATA
Net Sales Rs m164,6663,724 4,421.6%  
Other income Rs m1,02023 4,532.4%   
Total revenues Rs m165,6863,747 4,422.3%   
Gross profit Rs m37,718395 9,553.6%  
Depreciation Rs m5,580338 1,649.3%   
Interest Rs m777354 219.4%   
Profit before tax Rs m32,380-275 -11,761.9%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,18332 25,894.6%   
Profit after tax Rs m24,229-307 -7,894.8%  
Gross profit margin %22.910.6 216.1%  
Effective tax rate %25.3-11.5 -220.2%   
Net profit margin %14.7-8.2 -178.5%  
BALANCE SHEET DATA
Current assets Rs m121,8782,638 4,620.7%   
Current liabilities Rs m86,8062,305 3,766.6%   
Net working cap to sales %21.38.9 238.2%  
Current ratio x1.41.1 122.7%  
Inventory Days Days130135 95.9%  
Debtors Days Days6846 147.6%  
Net fixed assets Rs m81,0374,871 1,663.7%   
Share capital Rs m586123 474.8%   
"Free" reserves Rs m116,2183,496 3,324.6%   
Net worth Rs m116,8043,619 3,227.4%   
Long term debt Rs m4,5121,374 328.3%   
Total assets Rs m211,0527,509 2,810.8%  
Interest coverage x42.70.2 19,133.5%   
Debt to equity ratio x00.4 10.2%  
Sales to assets ratio x0.80.5 157.3%   
Return on assets %11.80.6 1,876.9%  
Return on equity %20.7-8.5 -244.6%  
Return on capital %27.41.6 1,729.2%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m80,7270-   
Fx outflow Rs m34,700517 6,718.4%   
Net fx Rs m46,027-517 -8,911.3%   
CASH FLOW
From Operations Rs m19,548514 3,800.2%  
From Investments Rs m-19,570-123 15,897.2%  
From Financial Activity Rs m8,642-387 -2,232.4%  
Net Cashflow Rs m8,9224 212,431.0%  

Share Holding

Indian Promoters % 54.1 32.9 164.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.2 4,416.7%  
FIIs % 27.7 0.6 4,775.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 66.4 15.4%  
Shareholders   69,601 20,121 345.9%  
Pledged promoter(s) holding % 8.6 36.4 23.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  FULFORD INDIA  DR. REDDYS LAB  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 71 Points Lower; Metal and Energy Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile trading day marginally lower.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 24, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS